publication . Article . 2021

Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance

Le Vu, Stéphane; Jones, Gabrielle; Anna, François; Rose, Thierry; Richard, Jean-Baptiste; Bernard-Stoecklin, Sibylle; Goyard, Sophie; Demeret, Caroline; Helynck, Olivier; Escriou, Nicolas; ...
Open Access English
  • Published: 01 Dec 2021
  • Publisher: HAL CCSD
  • Country: France
Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05–0.88) mid-March, 4.14% (95% CI: 3.31–4.99) mid-April and 4.93% (95% CI: 4.02–5.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infe...
Persistent Identifiers
free text keywords: [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, Article, Viral infection, Epidemiology, Science, Q
Related Organizations
Any information missing or wrong?Report an Issue